Prostate Specific Antigen News and Research RSS Feed - Prostate Specific Antigen News and Research

Novel imaging technique shows promise to detect, monitor and guide therapy for prostate cancer

Novel imaging technique shows promise to detect, monitor and guide therapy for prostate cancer

An international group of researchers report success in mice of a method of using positron emission tomography scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. [More]
Crowdsourcing new prediction tool for better prognosis of metastatic castration-resistant prostate cancer

Crowdsourcing new prediction tool for better prognosis of metastatic castration-resistant prostate cancer

Knowing the likely course of cancer can influence treatment decisions. Now a new prediction model published today in Lancet Oncology offers a more accurate prognosis for a patient's metastatic castration-resistant prostate cancer. [More]
Study questions recommendation against PSA screening

Study questions recommendation against PSA screening

Since the U.S Preventative Services Task Force recommended against prostate-specific antigen (PSA) screening for prostate cancer, there has been a significant decrease in the number of prostate biopsies and prostate cancer surgeries across the nation, report researchers. [More]
Risk and reality do not always match up in prostate cancer biopsies, research suggests

Risk and reality do not always match up in prostate cancer biopsies, research suggests

When it comes to prostate cancer biopsies, risk and reality don't always match up, according to research published online today in the Journal of Clinical Oncology. [More]
Revised prostate cancer guidelines did not reduce usage of PSA tests, study finds

Revised prostate cancer guidelines did not reduce usage of PSA tests, study finds

Controversy over prostate cancer screening guidelines that discourage use of PSA tests did not significantly reduce use of the test, a five-year review of more than 275,000 visits at UT Southwestern Medical Center showed. [More]
C-11 choline PET and MRI help physicians map patterns of prostate cancer recurrence after surgery

C-11 choline PET and MRI help physicians map patterns of prostate cancer recurrence after surgery

A team of Mayo Clinic researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery. Using C-11 choline PET imaging and multiparametric MRI, researchers found an anatomically diverse pattern of recurrence, which may help optimize treatment of patients whose prostate cancer returns after surgery. [More]
Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology. [More]
Researchers identify, validate three distinct molecular subtypes of prostate cancer

Researchers identify, validate three distinct molecular subtypes of prostate cancer

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology. [More]
PSA failure linked to increased risk of death among healthy men

PSA failure linked to increased risk of death among healthy men

A new study by investigators at Brigham and Women's Hospital has found that a rise in prostate-specific antigen (PSA) levels in healthy men who have previously been treated for prostate cancer is significantly associated with a 1.6-fold increased risk of death. [More]
VALIDATE D-Dimer kit from LGC Maine Standards receives US FDA approval for use on hemostasis test systems

VALIDATE D-Dimer kit from LGC Maine Standards receives US FDA approval for use on hemostasis test systems

LGC Maine Standards is pleased to announce our VALIDATE D-Dimer calibration verification / linearity test kit has received US FDA 510(k) clearance for use on Instrument Laboratory ACL TOP hemostasis test systems. [More]
Management of prostate cancer varies by race

Management of prostate cancer varies by race

A study published in The Journal of Urology® indicates that treatment for low-risk prostate cancer, rather than watchful waiting, is most likely to be sought by black men. [More]
Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance (AS) has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low risk prostate cancer. [More]
VCU Health radiologist uses MRI technology to detect difficult prostate cancers

VCU Health radiologist uses MRI technology to detect difficult prostate cancers

For three years, Andrew Harder wondered if he had prostate cancer. In 2009, he had routine blood work that revealed an elevated prostate-specific antigen (PSA) level. [More]
New study reports significant increase in new metastatic prostate cancer cases

New study reports significant increase in new metastatic prostate cancer cases

The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports a new Northwestern Medicine study. [More]
Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case Western Reserve University and Johns Hopkins Medical Institutions shows. [More]
Scientists create protein signatures for accurate diagnosis of prostate cancer

Scientists create protein signatures for accurate diagnosis of prostate cancer

Researchers at the Ontario Institute for Cancer Research and University Health Network in Toronto, along with researchers at the Eastern Virginia Medical School, have created protein signatures that accurately diagnose prostate cancer and can distinguish between patients with aggressive versus non-aggressive disease using a simple urine sample. [More]
NYU Lutheran helps patients fight prostate cancer with latest diagnostic and robotic surgery technology

NYU Lutheran helps patients fight prostate cancer with latest diagnostic and robotic surgery technology

Leading NYU Lutheran's fight is Marc Bjurlin, DO, the hospital's newly appointed director of urologic oncology and clinical assistant professor of urology at NYU School of Medicine. [More]
Screening PSA levels in younger men could accurately predict future risk of prostate cancer

Screening PSA levels in younger men could accurately predict future risk of prostate cancer

Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk. [More]
Advertisement
Advertisement